[371] Impact of HPV Vaccination on HPV Genotypes in Women with Atypical Cells of Undetermined Significance (ASC-US) in a Low-Risk Screening Population.

Roberto G Gamez, Stefan E Pambuccian, Bharat Thyagarajan, Shelly M Cook, Samy Amirouche, Evin H Gulbahce. University of Minnesota, Minneapolis

Background: HPV vaccination with the quadrivalent vaccine Gardasil® was approved by the FDA in June 2006 for use in females aged 9 to 26 and may also be useful in women aged 27-45. To date 44.3% of all U.S. females aged 13-17 have recieved at least one dose (MMWR 2010;59:1018-23). The aim of this study was to determine the potential impact of HPV vaccination on the HPV genotypes detected in women with ASC-US.
Design: All liquid-based (Surepath®) Pap tests diagnosed as ASC-US from 12/3/2002 to 6/30/2009 who had concomitant HPV genotyping were identified. Pap tests were diagnosed according to the 2001 Bethesda System; HPV tests were performed by a "home-brew" PCR-based method using the MY9/11 L1 consensus primers. The 13 HPV types included in the hc2 cocktail (16,18,31,33,35,39,45,51,52,56,58,59,68) were considered as high-rik HPV (HR-HPV). During the study period there were no major changes our screening population, laboratory personnel or molecular methods used. The study interval was divided into two periods: "pre-vaccination" (12/3/2002-6/30/2006) and "post-vaccination" (7/1/2006-6/30/2009). The frequecies of HPV 6, 11, 16 and 18 were compared between the two periods using χ2.
Results: During the study period our laboratory processed 391,845 Pap tests.

 Total Pap tests% ASC-USASC-US Age (mean± SD)ASC/SIL ratio
Pre-vaccination period215,7845.31%35.14 ± 12.892.48
Post-vaccination period176,0614.96%35.62 ± 13.161.88
Total391,8455.15%P val .0182.18


16594 cases of ASC-US from women aged 11 to 89 (mean, 35.37 ± 13.02 SD) with concomitant valid HPV genotyping results were identified.

 Number ASC-USany HPV typehr-HPV+HPV6HPV11HPV16HPV18
Pre-Vaccine86363767 (35.3%)1773(16.65)202 (6.3%)24 (0.7%)634 (19.7%)155 (4.8%)
Post-Vaccine79583284 (42.0%)1666 (20.9%)171 (5.5%)28(0.9%)522(17.7%)169 (5.4%)
p value <.001<.001.182.578.039.305


There was an increase in the total HPV+ and HR-HPV+ rate in the post-vaccination period, most likely due to the more restrictive criteria for the diagnosis of ASC-US in this period, reflected in the lower ASC-US and ASC/SIL ratios. Despite this increase in the frequency of overall HPV+ and HR-HPV+ cases, there was a significant reduction in HPV16+ ASC-US cases.
Conclusions: Our study shows that, despite the relatively low vaccination rate, the incomplete vaccination status and the targeting of only younger women, HPV vaccination has resulted in a decrease of HPV16 as a cause of ASC-US in our population.
Category: Cytopathology

Monday, February 28, 2011 9:30 AM

Poster Session I Stowell-Orbison/Surgical Pathology/Autopsy Awards Poster Session # 58, Monday Morning

 

Close Window